FDA Approves Voceryq for Recurrent Respiratory Papillomatosis
Developed by Inovio Pharmaceuticals, Voceryq is a plasmid DNA-based immunotherapy that harnesses the body’s own immune system to fight the underlying cause of RRP.
Developed by Inovio Pharmaceuticals, Voceryq is a plasmid DNA-based immunotherapy that harnesses the body’s own immune system to fight the underlying cause of RRP.
Women treated with Merck’s sacituzumab tirumotecan (sac-TMT) had a 41% lower risk of endometrial cancer progression than those receiving standard chemotherapy after immunotherapy, according to Phase 3 trial data.
The US FDA approval introduces a new adjuvant treatment option for stage III dMMR colon cancer, with Roche stating that Tecentriq combined with chemotherapy could become the new standard of care.
The growth of the oncology drugs market is driven by rising cancer prevalence, advancements in targeted therapies and immunotherapy, and the expansion of precision medicine.
Johnson & Johnson said the CHMP opinion is an important step towards positioning the off-the-shelf immunotherapy combination of teclistamab and daratumumab as a potential new standard of care earlier in the multiple myeloma treatment pathway.